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Inflammatory cytokines have been associated with the pathophysiology of hypertension and target organ damage (TOD). Resistant
hypertensive patients (RHTN) are characterized by poor blood pressure control and higher prevalence of TOD. This study
evaluated the relationship between plasma levels of TNF-𝛼 and arterial stiffness (pulse wave velocity—PWV) in 32 RHTN and 19
normotensive subjects. Moreover, we investigated the effect of TNF-𝛼 inhibition on human endothelial cells (HUVECs) incubated
with serum from RHTN and normotensive subjects. HUVECs containing serum obtained from normotensive (𝑛 = 8) and
hypertensive (𝑛 = 8) individuals were treated with TNF-𝛼 inhibitor (infliximab). Cell suspensions were used for measurement
of DNA fragmentation and reactive oxygen species (ROS) content. RHTN patients showed higher levels of TNF-𝛼 compared to
normotensive subjects, as well as higher PWV. Positive correlation was found between TNF-𝛼 levels and PWV measures in the
whole group. HUVECs incubated with serum from RHTN showed increased cell apoptosis and higher ROS content compared
to normotensive subjects. Infliximab attenuated the apoptosis of HUVECs incubated with serum from RHTN, but no effect in
ROS production was observed. Our findings suggest that TNF-𝛼 might mediate, at least in part, vascular damage in resistant
hypertension.
1. Introduction
Several studies have demonstrated the participation of
inflammatory cytokines in the genesis of hypertension in
humans [1, 2] and animal models [3, 4]. Mice lacking T
cells (RAG-1−/− mice) showed attenuated hypertension after
angiotensin II infusion and desoxycorticosterone acetate-
(DOCA-) salt or norepinephrine administration [3, 5]. More-
over, increased secretion of cytokines such as IFN-𝛾, IL-
17A, and TNF-𝛼 by circulatory spleen-derived T cells was
observed in Ang II-induced hypertension. In these animals,
the inhibition of TNF-𝛼 prevented increased vascular super-
oxide production and hypertension mediated by angiotensin
II [3]. Although it has been suggested that several cytokines
are involved in vascular damage induced by hypertension,
TNF-𝛼 inhibition decreases blood pressure and prevents tar-
get organ damage in animal studies [3, 6]. Also, the inhibition
of TNF-𝛼 in humans showed BP reduction [7]. On the other
hand, the role of this cytokine in hypertensive subjects has
been poorly studied.
Resistant hypertensive patients (RHTN) represent
extreme phenotype of hypertension, characterized by poor
blood pressure control and higher prevalence of target organ
damage, which explain the unfavorable prognosis associated
with this condition [8]. Vascular injury is a frequent
characteristic induced by hypertensive disease. Our group
showed that RHTN have higher arterial stiffness and
impaired endothelial function compared to normotensive
and mild to moderate subjects [9]. Conductance vessels
gradually show reduction in distensibility and compliance,
phenomena known as arterial stiffness. Arterial stiffness is
an independent predictor of all-cause and cardiovascular
mortality in hypertensive patients and is characterized by
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structural changes in connective tissue proteins in the
vascular wall [10]. In addition to extracellular matrix remod-
eling, oxidative stress and inflammatory markers are key
players in vascular remodeling associated with hypertension.
Angiotensin II stimulates NADPH oxidase activity, increases
reactive oxygen species production (ROS), and reduces
NO availability leading to endothelial dysfunction [11, 12].
In addition, ROS increases collagen secretion by vascular
smooth cells [13], which may favor vascular stiffness. Both
Ang II and ROS signaling activate cytokines production,
including TNF-𝛼, and the expression of cell adhesion
molecules including VCAM-1 and MCP-1 [14, 15]. In turn,
vascular inflammation stimulates vascular fibrosis and
smooth muscle cells proliferation, subsequently increasing
arterial stiffness [15]. Inflammatory markers such as TNF-𝛼,
C-reactive protein, and interleukin-6 are correlated with
arterial stiffness in hypertensive subjects [16]. In fact,
previous studies demonstrated that the infusion of
angiotensin II in mice lacking T and B cells (RAG-1−/−)
or interleukin-17a (IL-17a−/−) reduces collagen deposition in
the aorta and superoxide production and preserved endothe-
lium-dependent vasodilatation compared to wild type
animals [17, 18]. Interestingly, human aortic smooth muscle
cells treated concomitantly with IL-17 plus TNF-𝛼 showed
increased expression of several genes related to vascular
dysfunction and inflammation [18]. Taken together, these
data demonstrated that T cells-derived cytokines may play a
critical role in vascular stiffening.
We recently found that TNF-𝛼 inhibition with infliximab
reduced systolic BP, left ventricular hypertrophy, and vascular
inflammation in spontaneously hypertensive rats (SHR) [6].
Moreover, hypertensive subjects showed increased arterial
stiffness and higher plasma levels of TNF-𝛼 compared with
normotensive subjects [19]. TNF-𝛼 inhibition has been dis-
cussed as potential strategy to improve vascular function
[20, 21]. On the other hand, the treatment with anti-TNF-𝛼
improves vascular endothelial function and decreases arterial
stiffness in postmenopausal women [22] and rheumatoid
arthritis patients [23].
Despite some studies suggesting TNF-𝛼 as a potential
marker of vascular inflammation, the causal role of this
cytokine in the pathogenesis of hypertension is under-
explored. The association of TNF-𝛼 has been extensively
reported in hypertension, but no previous study evaluated the
effects of TNF-𝛼 on human endothelial cells. Thus, this study
was designed to evaluate the relationship between plasma lev-
els of TNF-𝛼 and arterial stiffness in RHTN and normoten-
sive subjects. Moreover, we investigated the effect of TNF-𝛼
inhibition on human endothelial cells incubated with serum
from RHTN and normotensive subjects.
2. Methods
2.1. Patient Population. This cross-sectional study was per-
formed in theOutpatient ResistantHypertensionClinic at the
University of Campinas Hospital. Thirty-two patients classi-
fied as RHTN and 19 normotensive subjects were included
in this study. Resistant hypertension (RHTN) was defined
as blood pressure (BP) that remained above goals despite
the concurrent use of 3 antihypertensive agents of different
classes, including a diuretic, at optimal dose amounts. Also,
patients whose blood pressure was controlled but required
4 or more medications were also considered resistant [24].
Hypertensive patients were followed up and treated for at
least 6 months with regular scheduled appointments before
being characterized as resistant to treatments. Exclusion
criteria included secondary hypertension (identifiable and
removable causes of hypertension, including Conn’s or Cush-
ing’s syndrome, diabetes, renal artery stenosis, pheochromo-
cytoma, and coarctation of the aorta), liver and renal disease,
heart failure (ejection fraction < 50%), stroke, peripheral vas-
cular disease, smokers, obesity (BMI ≥ 30 kg/m2), pregnancy
or oral contraceptive use, history or clinical evidence of recent
infection, and use of anti-inflammatory drugs.
2.2. Laboratory Assessments. Blood samples were collected at
8:00 a.m. after overnight fasting. The plasma levels of TNF-𝛼
were determined by ELISA (R&DSystems, Inc.,Minneapolis,
USA) according to manufacturer’s instructions. Biochemical
assessments, including serum cholesterol, LDL,HDL, triglyc-
erides, glucose, aldosterone, and creatinine, were performed
by central laboratory at the University of Campinas Hospital.
2.3. PWV Measurement. Pulse wave velocity was measured
using the SphygmoCor System (Atcor Medical, Sydney, Aus-
tralia) with the patient in the supine position. Pulse wave of
the carotid and femoral arteries was determined by estimat-
ing the delay with respect to the electrocardiogram wave. A
measuring tape was used to measure the distance from the
sternal notch to the carotid-femoral recording site. Carotid-
femoral PWVwas calculated by dividing traveled distance by
transit time (PWV = distance/time). At least two measure-
ments were performed in each patient. The PWV value was
reported as the mean and the values were corrected for mean
arterial pressure.
2.4. Collection and Preparation of Serum Samples. At the
study visit, blood was collected by antecubital vein puncture
using serum-separating tubes (BD Vacutainer System). After
30minutes of resting at room temperature, whole blood sam-
ples were centrifuged for 10minutes at 4,000 rpm. Serumwas
stored at −80∘C in 1mL aliquots until the cytokine measure-
ments.
2.5. Human Umbilical Vein Endothelial Cells (HUVECs) Cell
Culture and Plasma Incubation Conditions. HUVEC cell
lines (CRL-2873, ATCC, Manassas, VA, USA) were cultured
at 37∘C in 5% CO
2
in Dulbecco’s Modified Eagle’s Medium
(Vitrocell Embriolife, Brazil), supplemented with glucose
4,500mg/L and 10% (v/v) fetal bovine serum (FBS). The
cells were used at passage 3 for the experiments. HUVECs
were plated in 6-well plates at a density of 2 × 105 cells/well
(for flow cytometry assays) and in 25 cm2 tissue culture
flasks at a density of 4 × 105 cells/flask (for gene expression
experiments). After 24 hours, the medium was replaced by
FBS-free medium containing 10% of serum obtained from
normotensive (𝑛 = 8) and hypertensive (𝑛 = 8) individuals.
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Table 1: Primers sequences.
Name Forward primer (sense) 5󸀠 → 3󸀠 Reverse primer (antisense) 5󸀠 → 3󸀠
Human GAPDH GTTAGGAAAGCCTGCCGGT AGTTAAAAGCAGCCCTGGTGA
Human ENOS GTGGCTGTCTGCATGGACCT CCACGATGGTGACTTTGGCT
Human INOS GATCAAAAACTGGGGCAGCG CTCATCTGGAGGGGTAGGCT
Human ARGII TTAGCAGAGCTGTGTCAGATGGCT GGGCATCAACCCAGACAACACAAA
Human CAT ACAGCAAACCGCACGCTA CACGGGGCCCTACTGTAATAA
GAPDH: glyceraldehyde-3-phosphate dehydrogenase, ENOS: endothelial nitric oxide (NO) synthase, INOS: inducible NO synthase, ARGII: arginase II, and
CAT: catalase.
The cells were incubated for additional 24 hours with the
patients’ serum. The experiments were performed in dupli-
cate. When used, infliximab (400𝜇g/mL) was added to the
cells concomitantly with human serum.
2.6. Flow Cytometry Analysis of DNA Fragmentation and
Reactive Oxygen Species (ROS) Content. The medium was
discarded and adherent cells were washed with Krebs buffer.
The cells were detached using a cell scraper. Cell suspensions
were divided into two aliquots used formeasurement of DNA
fragmentation and ROS content.
For DNA fragmentation measurements, cells were cen-
trifuged (2,000×g, 4∘C for 10min) and the pellets were
resuspended in 250 𝜇L of DNA fragmentation buffer (PBS
containing 0.1% Triton X-100, 8 𝜇g/mL propidium iodide,
and 10mg/mL sodium citrate) and incubated overnight at
4∘C. After the incubation, samples were analyzed using a
FACSCalibur flow cytometer (Becton Dickinson, San Juan,
PR, USA). Fluorescence of 10,000 events was acquired in the
FL2 channel and analyzed using the CellQuest software. The
cellswith fragmentedDNAemitted lower fluorescence signal,
compared to cells with intact diploid and tetraploid DNA,
which emitted characteristic two-peaked high-intensity flu-
orescence. The percentage of apoptotic cells was calculated
using the number of low fluorescence events.
For ROS content measurements, cells were incubated
with 1mL of Krebs buffer containing 5mM 2,7-dichlorodi-
hydrofluorescein diacetate (DCFH) (Sigma, catalog number:
D6883) for 30min at room temperature. After incubation,
samples were analyzed using a FACSCalibur flow cytometer.
Fluorescence of 10,000 events was acquired in the FL1
channel and analyzed using theCellQuest Pro software.Mean
fluorescence was obtained from a M1 population defined in
the histograms. The limits for the M1 population were set
based on the fluorescence of the unstained cells.
2.7. Real-Time Reverse Transcription Polymerase Chain Reac-
tion. The total RNA was extracted from 25 cm2 tissue cul-
ture flasks using QIAzolLysis Reagent (Qiagen, Germany)
according to manufacturer’s instructions. The concentra-
tion and purity of the isolated RNA were determined
usingUV spectrophotometry (NanoDrop,Thermo Scientific,
Waltham, MA, USA). The integrity of the RNA was verified
using agarose gel electrophoresis stained with ethidium
bromide. Reverse transcriptionwas performedusingTaqMan
Reverse Transcription Reagents (Life Technologies, Carlsbad,
CA, USA) using 1 𝜇g of total RNA. Real-time RT-PCR was
performed using SYBR Green (Applied Biosystems, ONT,
Canada, 367659). Specific sequences of the primers for
endothelial NO synthase (ENOS), inducible NO synthase
(INOS), catalase (CAT), arginase II (ARGII), and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) (Exxtend
Biotecnologia Ltda., Sao Paulo, Brazil) as a housekeeping gene
control are shown in Table 1. The primers were designed to
comprise at least one intron to minimize the noise due to
genomic contamination. The PCR parameters were an initial
denaturation (one cycle at 95∘C for 10min), denaturation and
annealing/amplification at 95∘C for 10 s and 60∘C for 30 s,
respectively, for 40 cycles, and amelting curve, 72∘C, with the
temperature gradually increasing (0.5∘C) to 95∘C.
2.8. Statistical Analysis. Continuous variables were expressed
as mean and standard deviation (SD). Normality of distri-
bution was assessed by Shapiro Wilk test. Mann-Whitney
test was used to compare clinical data in 2 groups, while 2-
tailed unpaired t-test was used to compare apoptosis andROS
content between 2 groups. Comparisons among more than
2 groups were performed using 1-way ANOVA with Tukey’s
post hoc test. Categorical data were presented in percentages
and compared by Fisher’s exact test. Spearman correlation
was performed between TNF-𝛼 and PWV. The level of
significance (𝛼) accepted was less than 0.05.
3. Results
3.1. Characteristics of Study Participants. General patients’
characteristics are shown in Table 2. Normotensive and
RHTN groups showed similar characteristics such as age,
gender, body mass index, and systolic, diastolic, and pulse
pressure. Resistant hypertensive patients showed higher lev-
els of TNF-𝛼 compared to normotensive subjects (3.3 versus
2.1 pg/mL), as well as higher PWV (10.5 versus 7.2m/s), rep-
resented in Figure 1. Statistically significant correlation was
found betweenTNF-𝛼 levels and PWVmeasures in thewhole
group (Figure 1).
3.2. Effect of Infliximab on Endothelial Cell Apoptosis and
Reactive Oxygen Species (ROS) Production. HUVECs incu-
bated with serum from RHTN showed increased cell apop-
tosis (4.43 ± 1.9 versus 7.28 ± 1.5%; 𝑝 = 0.02) and higher
reactive oxygen species (ROS) content (987 ± 181 versus
1231 ± 127 mean fluorescence values; 𝑝 = 0.01), compared
to normotensive subjects (Figure 2). The treatment with
infliximab attenuated the apoptosis of HUVECs incubated
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Figure 1: (a) Pulse wave velocity (PWV) in normotensive subjects (NT) compared to resistant hypertensive patients (RHTN) (∗𝑝 < 0.05
versus NT). (b) Correlation between TNF-𝛼 levels and PWV in the whole group (𝑛 = 51; 𝑟 = 0.31; 𝑝 = 0.02).
Table 2: General characteristics of normotensive and resistant
hypertensive subjects.
NT
(𝑛 = 19)
RHTN
(𝑛 = 32) 𝑝 value
Age (years) 52 ± 5.0 57 ± 13 0.06
Gender (F/M) 9/10 19/13 0.56
BMI (kg/m2) 25.1 ± 2.3 26.3 ± 2.9 0.14
Office SBP
(mmHg) 121 ± 14 146 ± 16
∗
<0.0001
Office DBP
(mmHg) 78 ± 8 86 ± 14
∗ 0.04
Office PP
(mmHg) 43 ± 9 61 ± 13
∗
<0.0001
PWV (m/s) 7.2 ± 1.0 10.5 ± 2.2∗ <0.001
TNF-𝛼 (pg/mL) 2.1 ± 1.2 3.3 ± 3.1∗ 0.04
Mean ± SD. NT: normotensive subjects; RHTN: resistant hypertensive
patients; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic
blood pressure; PP: pulse pressure; PWV: pulse wave velocity; TNF-𝛼:
tumoral necrosis factor-𝛼. ∗𝑝 < 0.05 versus NT.
with serum from RHTN (7.28 ± 1.5 versus 5.97 ± 1.39%;
𝑝 = 0.04) but exerted no effect on ROS production. Although
we observed a tendency pointing to an increase, infliximab
did not change the apoptosis of HUVECs incubated with
normotensive serum (4.43 ± 1.9 versus 9.66 ± 9.95; 𝑝 = 0.13)
(Figure 3).
3.3. Gene Expression Profile inHUVECs Incubated with Serum
fromNormotensive and Resistant Hypertensive Subjects. Nor-
malized expression of the genes ENOS, INOS, CAT, and
ARGII was shown in Figure 4. While no differences in ENOS
expression were found between cells incubated with NT or
RHTN serum, we found increased ENOS expression after
treatment with infliximab only in the normotensive group
(Figure 4(a)). No differences in INOS and CAT expression
were observed among the groups. However, arginase II
(ARGII) expression was lower in HUVECs incubated with
serum of resistant hypertensive patients compared to nor-
motensive serum, but no effect of infliximab was found in
both groups.
4. Discussion
The present study demonstrated that resistant hypertensive
subjects have higher arterial stiffness and increased TNF-𝛼
plasma levels compared to normotensive subjects. Moreover,
TNF-𝛼 levels were positively correlated with carotid-femoral
PWV. We also found that endothelial cells incubated with
RHTN serum showed higher apoptosis rate than cells incu-
bated with serum from normotensive subjects.The treatment
with TNF-𝛼 inhibitor reduced apoptosis induced by RHTN
serum. The inhibition of TNF-𝛼 increased the expression
of ENOS in the cells incubated with normotensive serum,
but no changes in INOS, CAT, and ARGII expression were
observed. In addition, the expression of ARGII decreased in
cells incubated with RHTN compared to NT serum.
The contributions of immune system to cardiovascular
damage have been largely investigated. The lack of immune
cells prevents vascular damage and the development of
hypertension on several animal models of hypertension
as angiotensin II infusion and DOCA-salt [3, 25]. Taken
together, these findings suggest that the inhibition of inflam-
matory pathways may be beneficial for vascular damage
prevention and treatment of hypertension. Recent study from
our laboratory found that TNF-𝛼 inhibition reduced systolic
BP and left ventricular hypertrophy and activatedAKT/eNOS
pathway, improving vascular function in hypertensive rats
[6]. Indeed, higher levels of TNF-𝛼 and increased arterial
stiffness were found in hypertensive subjects compared with
normotensive subjects [19]. Also, arterial stiffness and TNF-
𝛼 were positively correlated in hypertensive patients [16].
Previous studies reported that TNF-𝛼 plasma levels are
associated with elevated blood pressure in apparently healthy
subjects [1, 2].
Since RHTN patients have increased arterial stiffness
and positive correlation with TNF-𝛼 levels, we investigated
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Figure 2: Percentage of apoptosis (a) and representative histograms overlay depicting fluorescence at FL2 (b) of HUVECs incubated with
DNA fragmentation buffer and previously treated with serum from normotensive individuals (NT, 𝑛 = 8) or resistant hypertensive patients
(RHTN, 𝑛 = 8). Mean ROS content (c) and representative histograms overlay depicting fluorescence at FL1 (d) from HUVECs incubated
with DHCF and previously treated with serum from NT (𝑛 = 8) or RHTN (𝑛 = 8) (∗𝑝 < 0.05 versus NT). Mean ± SD.The experiments were
performed in duplicate.
the effects of RHTN serum on endothelial cells in culture,
by measuring apoptosis percentage and ROS content and
whether those effects were mediated by TNF-𝛼. We found
that serum from RHTN promotes endothelial cells apoptosis
and increases ROS content. We found reduction in cell
apoptosis after the treatment with TNF-𝛼 inhibitor, but no
changes in ROS content. Corroborating with these findings,
we did not find changes in catalase gene expression after
TNF-𝛼 inhibition. Our findings suggest that TNF-𝛼 may
participate in apoptosis of endothelial cells but seems to not
affect oxygen species.
TNF-𝛼was also shown to stimulate endothelialmicropar-
ticles (EMPs) releasing, which is a marker of endothelial
dysfunction, and reactive oxygen species (ROS) produc-
tion, which suggest that ROS are important mediators of
TNF pathway [26]. Both higher ROS production and EMP
releasing were associated with apoptosis. These findings are
consistent with higher ROS content in HUVECs incubated
with resistant hypertensive serum. Accordingly, we previ-
ously demonstrated that isoprostane levels, an oxidative stress
marker, were associated with endothelial dysfunction in
RHTN patients [27]. However, as we did not observe reduc-
tion in ROS content with TNF-𝛼 inhibition, other factors
present in RHTN serum may be stimulating ROS formation.
The endothelium represents the main regulator of wall
homeostasis through releasing of several molecules such as
nitric oxide (NO) that is continuously produced by healthy
endothelial cells. L-arginine is converted intoNOby endothe-
lial NO synthase. Also, NO can be produced in response
to immunological stimuli through inducible NO synthase
(iNOS). Interestingly,HUVECs incubatedwithRHTNserum
had tendency of higher expression of eNOS compared to cells
treatedwithNT serum, irrespective of the increased endothe-
lial dysfunction found in those patients [9, 27]. Moreover, L-
arginine is also a substrate for arginase, an enzyme expressed
in the endothelium; TNF-𝛼 upregulates the expression of
arginase in ECs, which decreases L-arginine availability to
eNOS and leads to O−2 production. ROS production impairs
vasodilatation mediated by NO [20, 28]. Surprisingly, we
observed decreased arginase II (ARGII) expression in cells
treated with RHTN serum compared to cells incubated
with NT serum. Taken together, ECs treated with RHTN
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Figure 3: Percentage of apoptotic cells (cells with fragmented DNA) (a) and representative histograms overlay depicting fluorescence at
FL2 (b) of HUVECs incubated with DNA fragmentation buffer and previously treated with serum from normotensive individuals (NT,
𝑛 = 8) added with vehicle or infliximab. Percentage of apoptotic cells (cells with fragmented DNA) (c) and representative histograms overlay
depicting fluorescence at FL2 (d) ofHUVECs incubatedwithDNA fragmentation buffer and previously treatedwith serum fromhypertensive
patients (RHTN, 𝑛 = 8) addedwith vehicle or infliximab (∗𝑝 < 0.05 versus vehicle).Mean± SD.The experimentswere performed in duplicate.
serum showed higher eNOS expression concomitantly with
decreased ARGII expression. This enzymatic pattern would
favor NO bioavailability and vasodilation in this in vitro
system.Therefore, we may speculate that serum from RHTN
has substances able to stimulate NO production in our in
vitro system (functional endothelial cells) but endothelial
cells of the patients may not respond to these stimuli in
vivo, explaining the presence of endothelial dysfunction in
these patients [9]. We also observed that the treatment with
infliximab in cells incubated with serum from normotensive
subjects displayed increased eNOS expression, suggesting
that TNF-𝛼 might impair NO synthesis in ECs. Indeed,
animal study with estrogen-deficient rats treated with anti-
TNF-𝛼 had increased expression of tissue eNOS [29]. TNF-𝛼
has a crucial role in expression of eNOS suppressing eNOS
mRNA and protein levels by decreasing mRNA stability [30].
On the other hand, we do not discard the possibility
that TNF-𝛼 may modulate other NO synthases, as inducible
NO synthase (iNOS), promoting nitrosative stress and
endothelial dysfunction [31]; however, we found no statistical
differences in iNOS expression between the groups or after
infliximab treatment. We observed a large variability in
HUVECs gene expression incubated with serum from differ-
ent hypertensive subjects, which may reflect the differences
between patients including severity and time of hypertension,
presence of comorbidities, and differences in drug regimens.
The treatment of inflammatory disease (anti-neutrophil
cytoplasmic antibody-associated systemic vasculitis) with
infliximab improved endothelial function [32]; thus, TNF-𝛼
inhibitors have an emerging role in prevention of vascular
dysfunction. Furthermore, arterial stiffness was improved
in patients with rheumatoid arthritis treated with TNF-𝛼
inhibitors [21]. Further studies are needed to elucidate the
mechanisms of the proinflammatory cytokine TNF-𝛼 on
arterial stiffness. In conclusion, serum TNF-𝛼 in resistant
hypertensive subjects induces apoptosis in human endothe-
lial cells. These results suggest that TNF-𝛼 might mediate, at
least in part, vascular injury in resistant hypertension. Finally,
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Figure 4: Gene expression of serum-treated HUVECs. Expression of genes normalized for GAPDH was investigated in human umbilical
vein endothelial cells stimulated with plasma obtained from normotensive subjects (NT, 𝑛 = 8) or resistant hypertensive patients (RHTN,
𝑛 = 8) and treated with vehicle or infliximab. (a) Gene expression of endothelial nitric oxide synthase (ENOS). (b) Gene expression of catalase
(CAT). (c) Gene expression of inducible nitric oxide synthase (INOS). (d) Gene expression of arginase II (ARGII) (mean ± SD, ∗𝑝 < 0.05
versus NT vehicle). The experiments were performed in duplicate.
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